Overview
- The molecule 1D-142, originally developed for cancer, produced 40%–60% reductions in ALT and AST and lowered inflammation, necrosis and reactive oxygen species across three animal models.
- In ex vivo human liver explants from acute liver failure patients, treatment decreased necrosis and inflammatory signals, with no toxicity detected in healthy liver samples.
- The work was led by the Laboratorio de Hepatología Experimental y Terapia Génica (Universidad Austral/CONICET) with contributions from INTI and biotech partner Spectrum.
- The study has been accepted by Journal of Hepatology Reports and forms part of Bárbara Bueloni’s doctoral research under Guillermo Mazzolini and Juan Bayo.
- An international PCT patent is pending, and investigators report a newly identified molecule with potentially greater potency while emphasizing the findings remain preclinical and funding and trials are needed.